8-K: Ultragenyx Reports Q1 2024 Results, Reaffirms Full-Year Guidance and Provides Clinical Updates

Ultragenyx announced its first quarter 2024 financial results, reporting $109 million in total revenue and reaffirming its full-year revenue guidance, while also providing updates on its clinical programs.

Summary

• Ultragenyx reported total revenue of $109 million for the first quarter of 2024, an 8% increase compared to the same period in 2023.
• Crysvita revenue reached $83 million, a 9% increase year-over-year, with product sales in Latin America and Turkey growing by 71%.
• Dojolvi revenue was $16 million, a 14% increase compared to the first quarter of 2023.
• The company reaffirmed its 2024 total revenue guidance of $500 million to $530 million, with Crysvita revenue expected to be between $375 million and $400 million, and Dojolvi revenue between $75 million and $80 million.
• Operating expenses for the quarter totaled $274 million, including $37 million in non-cash stock-based compensation.
• The net loss for the quarter was $171 million, or $2.03 per share, compared to a net loss of $164 million, or $2.33 per share, in the first quarter of 2023.
• Net cash used in operations was $191 million, and the company had $569 million in cash, cash equivalents, and marketable debt securities as of March 31, 2024.
• The company completed enrollment for the Phase 3 studies of setrusumab for osteogenesis imperfecta and expects additional Phase 2 data in the second half of 2024.
• Positive interim Phase 1/2 data for GTX-102 in Angelman syndrome were presented, with plans to hold regulatory discussions in mid-2024 and initiate a Phase 3 trial before the end of the year.
• The last patient in Cohort 3 of the UX701 gene therapy study for Wilson disease has been dosed, with interim Stage 1 data expected in the second half of 2024.
• Dosing is complete in the Phase 3 study for DTX401 in Glycogen Storage Disease Type Ia, with data expected in the second quarter of 2024.
• The Phase 3 study for DTX301 in Ornithine Transcarbamylase Deficiency is ongoing, with enrollment expected to be completed in the second half of 2024.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the reaffirmed revenue guidance, positive clinical trial updates, and revenue growth. However, the net loss and cash burn temper the overall sentiment.

Positives

• Ultragenyx experienced an 8% increase in total revenue compared to the same quarter last year.
• Crysvita sales saw a 9% increase, driven by a 71% growth in Latin America and Turkey.
• Dojolvi revenue increased by 14% year-over-year.
• The company reaffirmed its full-year revenue guidance, indicating confidence in future performance.
• The GTX-102 program for Angelman syndrome showed positive interim Phase 1/2 data, with plans to move to Phase 3.
• Enrollment is complete for the Phase 3 studies of setrusumab for osteogenesis imperfecta, indicating progress in clinical development.
• The company is actively engaging with the FDA to seek an accelerated review path for UX111.

Negatives

• The company reported a net loss of $171 million for the quarter, although this was a slight improvement compared to the $164 million loss in the same period last year.
• Net cash used in operations was $191 million for the quarter.
• Operating expenses totaled $274 million, including $37 million in non-cash stock-based compensation.

Risks

• The company faces risks related to clinical drug development, including the unpredictability and lengthy process for obtaining regulatory approvals.
• There are risks related to potential side effects of product candidates.
• The company relies on third-party partners for certain activities.
• There are risks related to product liability lawsuits.
• The company is dependent on Kyowa Kirin for the commercial supply of Crysvita.
• There are risks related to fluctuations in buying or distribution patterns from distributors and specialty pharmacies.
• The transition back to Kyowa Kirin of exclusive rights to promote Crysvita in the United States and Canada could lead to unexpected costs, delays, or adverse impacts to revenue.
• There are risks related to smaller than anticipated market opportunities for the company's products and product candidates.
• Manufacturing risks and competition from other therapies or products could impact the company's performance.
• The company's future operating results and financial performance are subject to risks and uncertainties.

Future Outlook

The company reaffirmed its 2024 total revenue guidance of $500 million to $530 million, with Crysvita revenue expected to be between $375 million and $400 million, and Dojolvi revenue between $75 million and $80 million. They also expect annual operating expenses to be stable or decrease.

Management Comments

• Emil D. Kakkis, M.D., Ph.D., chief executive officer and president of Ultragenyx, stated that they continued to see rapid revenue growth in international markets and steady progress across their four commercial products.
• He also mentioned the completion of enrollment for the Phase 3 program in osteogenesis imperfecta and the overwhelming response to new data from the GTX-102 program for Angelman syndrome.

Industry Context

This announcement reflects the ongoing challenges and opportunities in the rare disease biopharmaceutical sector, where companies like Ultragenyx are focused on developing and commercializing treatments for underserved patient populations. The company's progress in clinical trials and revenue growth are key indicators of its performance in this competitive landscape.

Comparison to Industry Standards

• Ultragenyx's 8% revenue growth is a positive sign, but it is important to compare this to other companies in the rare disease space such as BioMarin Pharmaceutical Inc. which reported a 15% increase in total revenues in their most recent quarter.
• The 9% growth in Crysvita revenue is solid, but companies like Alexion Pharmaceuticals (now part of AstraZeneca) have seen higher growth rates for their rare disease products.
• The net loss of $171 million is typical for a company in the clinical stage of development, but it is important to monitor the trend of operating expenses and cash burn.
• The completion of enrollment for the Phase 3 studies of setrusumab is a positive milestone, but the success of the trials will be critical for future growth.
• The positive interim data for GTX-102 is promising, but it is important to compare the results to other gene therapy programs in development for Angelman syndrome, such as those from companies like Roche and Novartis.

Stakeholder Impact

• Shareholders will be interested in the revenue growth, clinical trial progress, and reaffirmed financial guidance.
• Employees will be impacted by the company's overall performance and future growth prospects.
• Patients and their families will be impacted by the progress of clinical trials and the potential for new therapies.
• Suppliers and creditors will be impacted by the company's financial health and ability to meet its obligations.

Next Steps

• Ultragenyx plans to hold regulatory discussions in mid-2024 with the goal of initiating a Phase 3 trial for GTX-102 before the end of the year.
• The company expects additional Phase 2 data update for setrusumab in the second half of 2024.
• Interim Stage 1 data for UX701 is expected in the second half of 2024.
• Phase 3 data readout for DTX401 is expected in the second quarter of 2024.
• Enrollment for the Phase 3 study of DTX301 is expected to be completed in the second half of 2024.

Key Dates

Keywords

Ultragenyx, Rare Diseases, Biopharmaceutical, Crysvita, Dojolvi, GTX-102, Angelman Syndrome, Osteogenesis Imperfecta, Gene Therapy, Clinical Trials, Financial Results, Revenue, Phase 3, FDA